China News Service, August 11th. According to the South American Overseas Chinese News Network, Peruvian social networks are circulating some false and untrue information about Sinopharm's new crown vaccine. In this context, the Peruvian "El Comercio" (El Comercio ) Recently published an article entitled "3 Reasons to Trust China's Sinopharm's New Coronary Vaccine", which listed the scientific data supporting the vaccine.

The article is excerpted as follows:

　　Reason 1: Validity data

　　The statement that "China's Sinopharm's new crown vaccine has no scientific research to prove its effectiveness and safety" is incorrect. The World Health Organization (WHO) scientific journals and independent experts, as well as academic institutions in Peru have all verified the positive effects of the vaccine.

　　After evaluating its Phase III clinical trial data, the WHO approved the emergency use of China's Sinopharm's new crown vaccine in May this year under the advice of the WHO independent expert group.

In the same month, the Journal of the American Medical Association (JAMA) released the vaccine’s Phase III clinical trial data, with an effective rate of 78%, which is higher than the minimum vaccine efficacy (50%) set by the WHO.

Data map: New crown vaccine produced by China National Pharmaceutical Group.

Photo by China News Agency reporter Jiang Qiming

　　Reason 2: Actual vaccination data in Peru and Argentina

　　Regarding the effectiveness of China's Sinopharm's new crown vaccine, there are not only clinical trial information, but also data on recent large-scale vaccination campaigns, such as Peru and Argentina.

Facts have proved that China's Sinopharm vaccine is very effective in the "real world".

　　In July of this year, researchers from the Peruvian National Institute of Health (INS), the Peruvian Social Medical Insurance Institute (EsSalud)’s Health Technology Evaluation and Research Institute (IETSI), and Peru’s Southern University of Science and Technology (UCS) published a study to vaccinate two After administering Sinopharm's new crown vaccine, the effectiveness of preventing deaths was 94%.

The subject of the study is more than 600,000 medical staff, they are the first people in Peru to receive this vaccine.

　　In Argentina, researchers also monitored the effectiveness of Sinopharm's new crown vaccine in preventing deaths among people over 60. The results showed that after the first dose of vaccine, the effective rate of preventing death from infection reached 61.6%. After the two doses were completed, The proportion rose to 84%.

Although the data is different from the results of the Peru study, this is because the research objects and research background are different, but in both cases, the Chinese National Medicine vaccine meets the international standards.

　　Reason 3: No serious adverse reactions

　　So far, no serious adverse reactions have been reported after a large number of China's Sinopharm's new crown vaccine has been used worldwide. According to data from the Peruvian National Center for Epidemiology, Disease Prevention and Control, Peru has not registered serious adverse reactions. In addition, the most common side effects of China's Sinopharm vaccine are pain at the injection site, fatigue, fever and headache, but these phenomena are temporary.